查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1624445

核醫學/放射性醫藥品的全球市場規模:各用途，手術數，各類型，各地區，範圍及預測

Global Nuclear Medicine/Radiopharmaceuticals Market Size By Application, By Procedural Volume, By Type, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

核醫/放射性藥物市場規模及預測

2020 年核醫/放射性藥物市場規模價值 65.6 億美元，預計到 2028 年將達到 135.3 億美元，2021 年至 2028 年的複合年增長率為 9.47%。

預測期內，神經系統應用對放射性藥物的需求將推動核醫/放射性藥物市場的成長。全球核子醫學/放射性藥物市場報告對市場進行了全面評估。它對關鍵細分市場、趨勢、市場推動因素、阻礙因素、競爭格局以及在市場中發揮關鍵作用的因素進行了全面的分析。

定義全球核醫/放射性藥物市場

為了診斷目的而給予患者並透過某些影像方式監測的放射性化合物稱為放射性藥物。放射性藥物用於治療和診斷目的。放射性藥物主要是帶有放射性同位素的有機分子。過去 50 年來，由於對化學的投入不斷增加以及放射性核素和放射性標記化合物的發展，核子醫學得到了長足的發展。

全球核子醫學/放射性藥物市場概況

全球核醫/放射性藥物市場的成長是由目標疾病的發生率和盛行率的增加所推動的。基於α鐵療法的標靶癌症治療的需求不斷增加，因此全球核醫/放射性藥物市場正在快速成長。

然而，一些阻礙因素正在限制全球核醫/放射性藥物市場的成長。放射性藥物的保質期短可能會阻礙全球核醫/放射性藥物市場的成長。此外，高昂的設備成本也可能阻礙全球核醫/放射性藥物市場的成長。

目錄

第1章 全球核醫學/放射性醫藥品市場簡介

  • 市場概要
  • 調查範圍
  • 前提條件

第2章 摘要整理

第3章 VERIFIED MARKET RESEARCH的調查手法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源一覽

第4章 全球核醫學/放射性醫藥品市場展望

  • 概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • 波特的五力分析
  • 價值鏈分析

第5章 核醫學/放射性醫藥品的全球市場:各用途

  • 概要
  • 診斷用途
    • SPECT用途
  • 其他的SPECT用途
    • PET用途
    • 治療用途
    • 甲狀腺
    • 骨轉移
    • 淋巴瘤
    • 內分泌腫瘤
    • 其他的治療用途

第6章 核醫學/放射性醫藥品的全球市場:手術數

  • 概要
  • 診斷手術
    • SPECT放射性醫藥品
    • PET放射性醫藥品
  • 治療手術
    • β線發送器
    • α射線放出核種
    • 近距離放射治療的同位素

第7章 全球核醫學/放射性醫藥品市場:各類型

  • 概要
  • 診斷用核醫學
    • SPECT放射性醫藥品
  • PET放射性醫藥品
    • F-18
    • 銣82
    • 其他的PET同位素
  • 治療用核醫學/放射性醫藥品
    • β線放出核種
    • α射線放出核種
    • 近距離放射治療的同位素

第8章 核醫學/放射性醫藥品的全球市場:各地區

  • 概要
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲各地區
    • 德國
    • 英國
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 全球其他地區
    • 南美
    • 中東·非洲

第9章 全球核醫學/放射性醫藥品市場競爭情形

  • 概要
  • 各公司的市場排行榜
  • 主要的開發策略

第10章 企業簡介

  • Cardinal Health, Inc.
  • Mallinckrodt PLC
  • GE Healthcare(A Fully-Owned Subsidiary of General Electric Company)
  • Lantheus Medical Imaging, Inc.
  • Bayer AG
  • Bracco Imaging S.P.A
  • Eczacibasi-Monrol Nuclear Products
  • Nordion, Inc.(A Subsidiary of Sterigenics International LLC.)
  • Advanced Accelerator Applications S.A.
  • Iba Molecular

第11章 附錄

  • 相關報告
簡介目錄
Product Code: 24378

Nuclear Medicine/Radiopharmaceuticals Market Size And Forecast

Nuclear Medicine/Radiopharmaceuticals Market size was valued at USD 6.56 Billion in 2020 and is projected to reachUSD 13.53 Billion by 2028, growing at aCAGR of 9.47% from 2021 to 2028.

The demand for radiopharmaceuticals in neurological applications will drive the growth of the Nuclear Medicine/Radiopharmaceuticals Market during the forecast period. The Global Nuclear Medicine/Radiopharmaceuticals Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Nuclear Medicine/Radiopharmaceuticals Market Definition

The radioactive compounds administered to the patient and monitored via a specific imaging device for diagnostic purposes are known as radiopharmaceuticals. This drug can be used for therapeutic or diagnostic purposes. The radiopharmaceuticals are mainly composed of a radioisotope bond to an organic molecule. Over the last 50 years, nuclear medicine has developed significantly owing to increasing investments in the field of chemistry and the development of radionuclides and radiolabeled compounds.

Global Nuclear Medicine/Radiopharmaceuticals Market Overview

The growth of the global Nuclear Medicine/Radiopharmaceuticals Market is being driven by increasing incidences and prevalence of target conditions. The demand for alpha radioimmunotherapy-based targeted cancer treatment is increasing and owing to which the global Nuclear Medicine/Radiopharmaceuticals Market is flourishing at a rapid pace.

However, some restraints are liming the growth of the global Nuclear Medicine/Radiopharmaceuticals Market. The short life span of radiopharmaceuticals may create setbacks for the growth of the global Nuclear Medicine/Radiopharmaceuticals Market. Also, the high equipment prices may hamper the growth of the global Nuclear Medicine/Radiopharmaceuticals Market.

Global Nuclear Medicine/Radiopharmaceuticals Market: Segmentation Analysis

The Global Nuclear Medicine/Radiopharmaceuticals Market is Segmented on the basis of Application, Procedural Volume, Type, and Geography.

Nuclear Medicine/Radiopharmaceuticals Market, By Application

  • 1.1 Diagnostic Applications
    • 1.1.1 SPECT Applications
    • 1.1.1.1 Cardiology
    • 1.1.1.2 Neurology
    • 1.1.1.3 Thyroid
  • 1.2 Other SPECT Applications
    • 1.2.1 PET Applications
    • 1.2.1.1 Oncology
    • 1.2.1.2 Cardiology
    • 1.2.1.3 Neurology
    • 1.2.1.4 Other PET Applications
    • 1.2.2 Therapeutic Applications
    • 1.2.3 Thyroid
    • 1.2.4 Bone Metastasis
    • 1.2.5 Lymphoma
    • 1.2.6 Endocrine Tumors
    • 1.2.7 Other Therapeutic Applications

Based on Application, the market is segmented into Diagnostic Applications and Other SPECT Applications. The diagnostic applications dominated the global Nuclear Medicine/Radiopharmaceuticals Market. The SPECT applications especially contributed majorly to the growth of the market.

Nuclear Medicine/Radiopharmaceuticals Market, By Procedural Volume

  • 2.1 Diagnostic Procedures
    • 2.1.1 SPECT Radiopharmaceuticals
    • 2.1.2 PET Radiopharmaceuticals
  • 2.2 Therapeutic Procedures
    • 2.2.1 Beta Emitters
    • 2.2.2 Alpha Emitters
    • 2.2.3 Brachytherapy Isotopes

Based on Procedural Volume, the market is segmented into Diagnostic Procedures and Therapeutic Procedures. The Diagnostic Procedures are further bifurcated into SPECT Radiopharmaceuticals, PET Radiopharmaceuticals, and Therapeutic Procedures. The Therapeutic Procedures are further bifurcated into Beta Emitters, Alpha Emitters, and Brachytherapy Isotopes. The Diagnostic Procedures dominated the global Nuclear Medicine/Radiopharmaceuticals Market.

Nuclear Medicine/Radiopharmaceuticals Market, By Type

  • 3.1 Diagnostic Nuclear Medicine
    • 3.1.1 SPECT Radiopharmaceuticals
    • 3.1.1.1 Tc-99m
    • 3.1.1.2 Tl-201
    • 3.1.1.3 Ga-67
    • 3.1.1.4 I-123
    • 3.1.1.5 Other SPECT Isotopes
  • 3.3 PET Radiopharmaceuticals
    • 3.2.1 F-18
    • 3.2.2 Rubidium-82
    • 3.2.3 Other PET Isotopes
  • 3.3 Therapeutic Nuclear Medicine/Radiopharmaceuticals
    • 3.3.1 Beta Emitters
    • 3.3.1.1 Iodine-131
    • 3.3.1.2 Y-90
    • 3.3.1.3 Sm-153
    • 3.3.1.4 Re-186
    • 3.3.1.5 Lu-177
    • 3.3.1.6 Other Beta Emitters
    • 3.3.2 Alpha Emitters
    • 3.3.2.1 Ra-223
    • 3.3.3 Brachytherapy Isotopes
    • 3.3.3.1 Iodine-125
    • 3.3.3.2 Iridium-192
    • 3.3.3.3 Palladium-103
    • 3.3.3.4 Cesium-131
    • 3.3.3.5 Other Brachytherapy Isotopes

Based on Type, the market is segmented into Diagnostic Nuclear Medicine, PET Radiopharmaceuticals, and Therapeutic Nuclear Medicine/Radiopharmaceuticals. The Therapeutic Nuclear Medicine/ Radiopharmaceuticals is further bifurcated into Beta Emitters, Alpha Emitters, and Brachytherapy Isotopes. The alpha emitters segment dominated the market.

Nuclear Medicine/Radiopharmaceuticals Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

Based on regional analysis, the Global Nuclear Medicine/Radiopharmaceuticals Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The largest share in the market will be dominated by North America. The dominance of the North American region can be attributed to the development of novel technologies for radioscopic production and an increase in government funding.

Key Players

  • The "Global Nuclear Medicine/Radiopharmaceuticals Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
  • Cardinal Health, Inc., Mallinckrodt PLC, GE Healthcare (A Fully-Owned Subsidiary of General Electric Company), Lantheus Medical Imaging, Inc., Bayer AG, Bracco Imaging S.P.A, Eczacibasi-Monrol Nuclear Products, Nordion, Inc. (A Subsidiary of Sterigenics International LLC.), Advanced Accelerator Applications S.A., Iba Molecular.
  • These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.

Key Developments

  • Partnerships, Collaborations and Agreements
  • A manufacturing and distribution deal was signed in 2019 between Eczacba-Monrol and Telix Pharmaceuticals Limited (Australia). Telix has engaged Eczacba-Monrol as a radiopharmaceutical production partner and distributor throughout Turkey, the Middle East, and North Africa, according to the conditions of the agreement.
  • Mergers and Acquisitions
  • In the year 2019, Curium acquired MAP Medical, allowing it to expand its footprint in Europe and gain direct access to the Nordic and Baltic countries.
  • Product Launches and Product Expansions
  • Curium (France) and NRG (Netherlands) inked a Molybdenum-99 manufacturing agreement in 2019.
  • Cobalt-60 was purchased from the Board of Radiation and Isotope Technology (BRIT) in April 2019 for distribution throughout Europe by Nordion, Inc.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION

  • 5.1 Overview
  • 5.2 Diagnostic Applications
    • 5.2.1 SPECT Applications
    • 5.2.1.1 Cardiology
    • 5.2.1.2 Neurology
    • 5.2.1.3 Thyroid
  • 5.3 Other SPECT Applications
    • 5.3.1 PET Applications
    • 5.3.1.1 Oncology
    • 5.3.1.2 Cardiology
    • 5.3.1.3 Neurology
    • 5.3.1.4 Other PET Applications
    • 5.3.2 Therapeutic Applications
    • 5.3.3 Thyroid
    • 5.3.4 Bone Metastasis
    • 5.3.5 Lymphoma
    • 5.3.6 Endocrine Tumors
    • 5.3.7 Other Therapeutic Applications

6 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY PROCEDURAL VOLUME

  • 6.1 Overview
  • 6.2 Diagnostic Procedures
    • 6.2.1 SPECT Radiopharmaceuticals
    • 6.2.2 PET Radiopharmaceuticals
  • 6.3 Therapeutic Procedures
    • 6.3.1 Beta Emitters
    • 6.3.2 Alpha Emitters
    • 6.3.3 Brachytherapy Isotopes

7 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE

  • 7.1 Overview
  • 7.2 Diagnostic Nuclear Medicine
    • 7.2.1 SPECT Radiopharmaceuticals
    • 7.2.1.1 Tc-99m
    • 7.2.1.2 Tl-201
    • 7.2.1.3 Ga-67
    • 7.2.1.4 I-123
    • 7.2.1.5 Other SPECT Isotopes
  • 7.3 PET Radiopharmaceuticals
    • 7.3.1 F-18
    • 7.3.2 Rubidium-82
    • 7.3.3 Other PET Isotopes
  • 7.4 Therapeutic Nuclear Medicine/ Radiopharmaceuticals
    • 7.4.1 Beta Emitters
    • 7.4.1.1 Iodine-131
    • 7.4.1.2 Y-90
    • 7.4.1.3 Sm-153
    • 7.4.1.4 Re-186
    • 7.4.1.5 Lu-177
    • 7.4.1.6 Other Beta Emitters
    • 7.4.2 Alpha Emitters
    • 7.4.2.1 Ra-223
    • 7.4.3 Brachytherapy Isotopes
    • 7.4.3.1 Iodine-125
    • 7.4.3.2 Iridium-192
    • 7.4.3.3 Palladium-103
    • 7.4.3.4 Cesium-131
    • 7.4.3.5 Other Brachytherapy Isotopes

8 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 EuropeRegional
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East & Africa

9 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Cardinal Health, Inc.
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Mallinckrodt PLC
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 GE Healthcare (A Fully-Owned Subsidiary of General Electric Company)
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Lantheus Medical Imaging, Inc.
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Bayer AG
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Bracco Imaging S.P.A
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Eczacibasi-Monrol Nuclear Products
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Nordion, Inc. (A Subsidiary of Sterigenics International LLC.)
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Advanced Accelerator Applications S.A.
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Iba Molecular
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 Appendix

  • 11.1 Related Reports